Literature DB >> 6314932

Evidence of proteolytic activation of Sendai virus in mouse lung.

M Tashiro, M Homma.   

Abstract

A device was made to analyze the pneumotropism of Sendai virus in mouse. Minced lung blocks were prepared from the mouse intranasally infected with Sendai virus for 2 hours and cultured in a CO2 incubator. This culture system provided a suitable in vitro model of Sendai virus infection in mice in terms of the distribution of the viral antigens and histopathological findings. The progeny virus recovered from the lung culture was already activated and was accompanied by the cleavage of F glycoprotein into F1 and F2. This fact demonstrates that the activating mechanism is reversed in the lung culture as found in vivo infection of mouse lung. The viral activation and the cleavage of F glycoprotein were simultaneously inhibited by tosyllysylchloromethylketone, leupeptin, soybean trypsin inhibitor and antipain, but not by tosylamidophenylethylchloromethyl-ketone, chymostatin, pepstatin, iodoacetamide, phenylmethylsulfonylfluoride and p-chloromercuribenzoate. These results show that the activating enzyme of Sendai virus found in the lung culture was similar to trypsin. The existence of the activating enzyme may support the replication of Sendai virus in mouse lung in multiple-step and also result in the lung pathology.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6314932     DOI: 10.1007/bf01309262

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  29 in total

1.  Host-controlled variation observed with Sendai virus grown in mouse fibroblast (L) cells.

Authors:  N ISHIDA; M HOMMA
Journal:  Virology       Date:  1961-08       Impact factor: 3.616

2.  A host-induced modification of hemagglutinating virus of Japan (HVJ, Sendai virus) in its hemolytic and cytopathic activity.

Authors:  T MATSUMOTO; K MAENO
Journal:  Virology       Date:  1962-08       Impact factor: 3.616

3.  Loss on serial passage of rhesus monkey kidney cells of proteolytic activity required for Sendai virus activation.

Authors:  S M Silver; A Scheid; P W Choppin
Journal:  Infect Immun       Date:  1978-04       Impact factor: 3.441

4.  Identification of biological activities of paramyxovirus glycoproteins. Activation of cell fusion, hemolysis, and infectivity of proteolytic cleavage of an inactive precursor protein of Sendai virus.

Authors:  A Scheid; P W Choppin
Journal:  Virology       Date:  1974-02       Impact factor: 3.616

5.  Restoration of the fusion activity of L cell-borne Sendai virus by trypsin.

Authors:  M Homma; S Tamagawa
Journal:  J Gen Virol       Date:  1973-06       Impact factor: 3.891

6.  A sensitive plaque assay for Sendai virus in an established line of monkey kidney cells.

Authors:  K Sugita; M Maru; K Sato
Journal:  Jpn J Microbiol       Date:  1974-05

7.  Separation of single-stranded ribonucleic acids by acrylamide-agarose-urea gel electrophoresis.

Authors:  R W Floyd; M P Stone; W K Joklik
Journal:  Anal Biochem       Date:  1974-06       Impact factor: 3.365

8.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

9.  Fluorographic detection of radioactivity in polyacrylamide gels with the water-soluble fluor, sodium salicylate.

Authors:  J P Chamberlain
Journal:  Anal Biochem       Date:  1979-09-15       Impact factor: 3.365

10.  Trypsin action on the growth of Sendai virus in tissue culture cells. IV. Evidence for activation of sendai virus by cleavage of a glycoprotein.

Authors:  M Ohuchi; M Homma
Journal:  J Virol       Date:  1976-06       Impact factor: 5.103

View more
  16 in total

1.  Pneumopathogenicity of a Sendai virus protease-activation mutant, TCs, which is sensitive to trypsin and chymotrypsin.

Authors:  M Itoh; T D Ming; T Hayashi; Y Mochizuki; M Homma
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

2.  Altered budding site of a pantropic mutant of Sendai virus, F1-R, in polarized epithelial cells.

Authors:  M Tashiro; M Yamakawa; K Tobita; J T Seto; H D Klenk; R Rott
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

3.  Comparison of protective effects of serum antibody on respiratory and systemic infection of Sendai virus in mice.

Authors:  M Tashiro; K Tobita; J T Seto; R Rott
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

Review 4.  Protease-dependent virus tropism and pathogenicity.

Authors:  Y Nagai
Journal:  Trends Microbiol       Date:  1993-06       Impact factor: 17.079

5.  A protease activation mutant, MVCES1, as a safe and potent live vaccine derived from currently prevailing Sendai virus.

Authors:  X L Wang; M Itoh; H Hotta; M Homma
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

6.  Protection of mice from wild-type Sendai virus infection by a trypsin-resistant mutant, TR-2.

Authors:  M Tashiro; M Homma
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

7.  Tryptase Clara, an activating protease for Sendai virus in rat lungs, is involved in pneumopathogenicity.

Authors:  M Tashiro; Y Yokogoshi; K Tobita; J T Seto; R Rott; H Kido
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

8.  Pneumopathogenicity in mice of a Sendai virus mutant, TSrev-58, is accompanied by in vitro activation with trypsin.

Authors:  Y Mochizuki; M Tashiro; M Homma
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

9.  Cell-mediated immunity induced in mice after vaccination with a protease activation mutant, TR-2, of Sendai virus.

Authors:  M Tashiro; Y Fujii; K Nakamura; M Homma
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

10.  Cleavage of the SARS coronavirus spike glycoprotein by airway proteases enhances virus entry into human bronchial epithelial cells in vitro.

Authors:  Yiu-Wing Kam; Yuushi Okumura; Hiroshi Kido; Lisa F P Ng; Roberto Bruzzone; Ralf Altmeyer
Journal:  PLoS One       Date:  2009-11-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.